Opioids and alcoholism

Physiology and Behavior

Volumn 81, Issue 2, 2004, Pages 339-358

  Oswald, L M ^a   Wand, G S ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

ACTH; Alcohol; Alcoholism; Cortisol; Family history of alcoholism; Genetics; Naloxone; Naltrexone; Opioid antagonists; Opioid peptides; Reinforcement; endorphin

Indexed keywords

4 AMINOBUTYRIC ACID; ARGIPRESSIN; BETA ENDORPHIN; CORTICOTROPIN; HYDROCORTISONE; NALMEFENE; NALOXONE; NALTREXONE; OPIATE; OPIATE ANTAGONIST; OPIATE PEPTIDE; OPIATE RECEPTOR; TETRACOSACTIDE;

ALCOHOL CONSUMPTION; ALCOHOLISM; BRAIN; CLINICAL TRIAL; DOPAMINE RELEASE; DRINKING BEHAVIOR; DRUG ABUSE; DRUG ACTIVITY; GASTROINTESTINAL DISEASE; GENE MUTATION; GENETICS; HUMAN; HYPOTHALAMUS; LIVER TOXICITY; NAUSEA; NEUROTRANSMISSION; NONHUMAN; PRIORITY JOURNAL; REINFORCEMENT; REVIEW; RISK FACTOR; STRESS;

EID: 2442658861     PISSN: 00319384     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.physbeh.2004.02.008     Document Type: Article

References (233)

1. Grant B.F. Alcohol consumption, alcohol abuse and alcohol dependence. The United States as an example. Addiction. 89:1994;1357-1365
2. Wise R., Rompre P. Brain dopamine and reward. Annu. Rev. Psychol. 40:1989;191-225
3. DiChiara G., Emperato A. Drugs abused by humans preferentially increase synaptic dopamine concentrations in the mesolimbic system of freely moving rats. Proc. Natl. Acad. Sci. U. S. A. 85:1988;5274-5278
4. Benjamin D., Grant E., Pohorecky A. Naltrexone reverses ethanol-induced dopamine release in the nucleus accumbens in awake freely moving rats. Brain Res. 621:1993;137-140
5. Gianoulakis C. Implications of endogenous opioids and dopamine in alcoholism: human and basic science studies. Alcohol Alcohol. 31(Suppl. 1):1996;33-42
6. Gianoulakis C. Influence of the endogenous opioid system on high alcohol consumption and genetic predisposition to alcoholism. J. Psychiatry Neurosci. 26:2001;304-318
7. Herz A. Endogenous opioid systems and alcohol addiction. Psychopharmacology. 129:1997;99-111
8. Sinclair J.D. Drugs to decrease alcohol drinking. Ann. Med. 22:1990;357-362
9. Ulm R.R., Volpicelli J.R., Volpicelli L.A. Opiates and alcohol self-administration in animals. J. Clin. Psychiatry. 56(Suppl. 7):1995;5-14
10. Cowen M.S., Lawrence A.J. The role of opioid-dopamine interactions in the induction and maintenance of ethanol consumption. Prog. Neuropsychopharmacol. Biol. Psychiatry. 23:1999;1171-1212
11. Trachtenberg M.C., Blum K. Alcohol and opioid peptides: neuropharmacological rationale for physical craving of alcohol. Am. J. Drug Alcohol Abuse. 13:1987;365-372
12. Reid L.D., Delconte J.D., Nichols M.L., Bilsky E.J., Hubbell C.L. Tests of opioid deficiency hypotheses of alcoholism. Alcohol. 8:1991;247-257
13. Koob G.F. Drugs of abuse: anatomy, pharmacology and function of reward pathways. Trends Pharmacol. Sci. 13:1992;177-184
14. Melendez R.E., Rodd-Henricks Z.A., Engleman E.A., Li T.K., McBride W.J., Murphy J.M. Microdialysis of dopamine in the nucleus accumbens of alcohol-preferring (P) rats during anticipation and operant self-administration of ethanol. Alcohol. Clin. Exp. Res. 26:2002;318-325
15. Wise R.A. Drug-activation of brain reward pathways. Drug Alcohol Depend. 51:1998;13-22
16. Drevets W.C., Gautier C., Price J.C., Kupfer D.J., Kinahan P.E., Grace A.A., et al. Amphetamine-induced dopamine release in human ventral striatum correlates with euphoria. Biol. Psychiatry. 49:2001;81-96
17. Martin-Soelch C., Leenders K.L., Chevalley A.-F., Missimer J., Kunig G., Magyar S., et al. Reward mechanisms in the brain and their role in dependence: evidence from neurophysiological and neuroimaging studies. Brain Res. Rev. 36:2001;139-149
18. Wise R.A. Neural mechanisms of the reinforcing action of cocaine. NIDA Res. Monogr. 50:1984;15-33
19. Johnson S.W., North R.A. Opioids excite dopamine neurons by hyperpolarization of local interneurons. J. Neurosci. 12:1992;483-488
20. Wise R.A. Addictive drugs and brain stimulation reward. Annu. Rev. Neurosci. 19:1996;319-340
21. Herz A., Spanagel R. Endogenous opioids and addiction. Tseng L.F. The pharmacology of opioids. 1995;445-462 Harwood, Germany
22. Philpot R.M., Kirstein C.L. The effects of repeated alcohol exposure on the neurochemistry of the periadolescent nucleus accumbens septi. NeuroReport. 9:1998;1359-1363
23. Weiss F., Lorang M.T., Bloom F.E., Koob G.F. Oral alcohol self-administration stimulates dopamine release in the rat nucleus accumbens: genetic and motivational determinants. J. Pharmacol. Exp. Ther. 267:1993;250-258
24. Samson H.H., Hodge C.W. The role of the mesoaccumbens dopamine system in ethanol reinforcement: studies using the techniques of microinjection and voltammetry. Alcohol Alcohol. (Suppl. 2):1993;469-474
25. 1 receptor gene expression attenuates alcohol seeking behavior. Eur. J. Pharmacol. 353:1998;149-158
26. Nakanishi S., Inoue A., Kita T., Nakamura M., Chang A.C., Cohen S.N., et al. Nucleotide sequence of cloned cDNA for bovine corticotropin-b-lipotropin precursor. Nature. 278:1979;423-427
27. Noda M., Teranishi Y., Takahashi H., Toyosato M., Notake M., Nakanishi S., et al. Isolation and structural organization of the human preproenkephalin gene. Nature. 297:1982;431-434
28. Kakidani H., Furutami Y., Takahashi H., Noda M., Mozimoto Y., Hiroshi T., et al. Cloning and sequence analysis of cDNA for porcine β-neoendorphin/ dynorphin precursors. Nature. 298:1982;245-249
29. Amalric M., Cline E.J., Marinez J.L., Bloom F.E., Koob G.F. Rewarding properties of β-endorphin as measured by conditioned place preference. Psychopharmacology. 91:1987;14-19
30. Mezey E., Kiss J., Mueller G.P., Eskay R., O'Donohue T.L., Palkovits M. Distribution of the pro-opiomelanocortin derived peptides (ACTH, alpha-MSH, beta-endorphin) in the rat hypothalamus. Brain Res. 328:1985;341-347
31. Spanagel R., Herz A., Bals-Kubik R., Shippenberg T.S. β-Endorphin-induced locomotor stimulation and reinforcement are associated with an increase in dopamine release in the nucleus accumbens. Psychopharmacology (Berl.). 104:1991;51-56
32. Wilcox J.N., Roberts J.L., Chronwall B.M., Bishop J.F., O'Donohue T. Localization of proopiomelanocortin mRNA in functional subsets of neurons defined by their axonal projections. J. Neurosci. Res. 16:1986;89-96
33. Mansour A., Khachaturian H., Lewis M.E., Akil H., Watson S.J. Anatomy of CNS opioid receptors. Trends Neurosci. 11:1988;308-314
34. Feldman R.S., Meyer J.S., Quenzer L.F. Principles of neuropsychopharmacology. 1997;Sinauer Associates, Sunderland (MA)
35. Khachaturian H., Lewis M.E., Schafer M.K.H., Watson S.J. Anatomy of the CNS opioid systems. Trends Neurosci. 10:1985;111-119
36. Reisine T., Bell G.I. Molecular biology of opioid receptors. Trends Neurol. Sci. 16:1993;506-510
37. 33P in situ hybridization study. Neuroscience. 88:1999;1093-1135
38. Davis V.E., Walsh M.J. Alcohol, amines and alkaloids: a possible biochemical basis for alcohol addiction. Science. 167:1970;1005-1007
39. Blum D., Hamilton M.G., Hirst M., Wallace J.E. Putative role of isoquinoline alkaloids in alcoholism: a link to opiates. Alcohol. Clin. Exp. Res. 2:1978;113-120
40. Fertel R.H., Greenwald J.E., Schwarz R., Wong L., Bianchine J. Opiate receptor binding and analgesic effects of the tetrahydroisoquinolines salsolinol and tetrahydro-papaveroline. Res. Commun. Chem. Pathol. Pharmacol. 27:1980;3-16
41. Hamilton M.G., Blum K., Hirst M. Identification of an isoquinoline alkaloid after chronic exposure to ethanol. Alcohol. Clin. Exp. Res. 2:1978;133-137
42. Boyadjieva N.I., Sarkar D.K. The role of cAMP in ethanol-regulated beta-endorphin release from hypothalamic neurons. Alcohol Clin. Exp. Res. 21:1997;728-731
43. Gianoulakis C. Characterization of the effect of acute ethanol administration on the release of β-endorphin peptides by the rat hypothalamus. Eur. J. Pharmacol. 180:1990;21-29
44. Gianoulakis C., Barcomb A. Effect of acute ethanol in vivo and in vitro on the β-endorphin system in the rat. Life Sci. 40:1987;19-28
45. Li X.-W., Li T.-K., Froehlich J.C. Enhanced sensitivity of the nucleus accumbens proenkephalin system to alcohol in rats selectively bred for alcohol preference. Brain Res. 794:1998;35-47
46. De Waele J.-P., Papachristou D., Gianoulakis C. The alcohol-preferring C57BL/6 mice present an enhanced sensitivity of the hypothalamic β-endorphin system to ethanol than the alcohol-avoiding DBA/2 mice. J. Pharmacol. Exp. Ther. 261:1992;788-794
47. Keith L.D., Crabbe J.C., Robertson L.M., Kendall J.W. Ethanol stimulated endorphin and corticotrophin secretion in vitro. Brain Res. 367:1986;222-229
48. De Waele J.-P., Gianoulakis C. Effects of single and repeated exposure to ethanol on hypothalamic β-endorphin and CRH release by the C57BL/6 and DBA/2 strains of mice. Neuroendocrinology. 57:1993;700-709
49. Schulz R., Wuster M., Duka T., Herz A. Acute and chronic ethanol treatment changes endorphin levels in brain and pituitary. Psychopharmacology. 68:1980;221-227
50. Seizinger B.R., Boverman K., Maysinger D., Hollt V., Herz A. Differential effects of acute and chronic ethanol treatment on particular opioid peptide systems in discrete regions of rat brain and pituitary. Pharmacol. Biochem. Behav. 18:1983;361-369
51. Milton G.V., Erickson C.K. Effect of ethanol and discomfort on brain Met-enkephalin levels in male Sprague-Dawley rats. Alcohol. Clin. Exp. Res. 15:1991;327
52. Scanlon M.N., Lazar-Wesley E., Grant K.A., Kunos G. Proopiomelanocortin messenger RNA is decreased in the mediobasal hypothalamus of rats made dependent on ethanol. Alcohol. Clin. Exp. Res. 16:1992;1147-1151
53. Gianoulakis C., de Waele J.-P. Genetic of alcoholism: role of the opioid system. Metab. Brain Dis. 9:1994;105-131
54. Boyadjieva N., Dokur M., Advis J.P., Meadows G.G., Sarkar D.K. Chronic ethanol inhibits NK cell cytolytic activity: role of opioid peptide β-endorphin. J. Immunol. 167:2001;5645-5652
55. Winkler A., Roske I., Furkert J., Fickel J., Melzig M.F. Effects of voluntary ethanol ingestion on the POMC gene expression in the rat pituitary and on the plasma beta-endorphin content. Alcohol Alcohol. 30:1995;231-238
56. Rasmussen D.D., Boldt B.M., Wilkinson C.W., Mitton D.R. Chronic daily ethanol and withdrawal: 3. Forebrain pro-opiomelanocortin gene expression and implications for dependence, relapse, and deprivation effect. Alcohol. Clin. Exp. Res. 26:2002;535-546
57. Boyadjieva N.I., Sarkar D.K. Effects of chronic alcohol on immunoreactive beta-endorphin secretion from hypothalamic neurons in primary cultures: evidence for alcohol tolerance, withdrawal, and sensitization responses. Alcohol. Clin. Exp. Res. 18:1994;1497-1501
58. Boyadjieva N., Sarkar D.K. Effects of ethanol on basal and adenosine-induced increases in beta-endorphin release and intracellular cAMP levels in hypothalamic cells. Brain Res. 824:1999;112-118
59. Pastorcic M., Boyadjieva N., Sarkar D.K. Comparison of the effects of alcohol and acetaldehyde on proopiomelanocortin mRNA levels and beta-endorphin secretion from hypothalamic neurons in primary cultures. Mol. Cell. Neurosci. 5:1994;580-586
60. Vescovi P.P., Coiro V., Volpi R., Giannini A., Passeri M. Plasma beta-endorphin but not Met-enkephalin levels are abnormal in chronic alcoholics. Alcohol Alcohol. 27:1992;471-475
61. Yirmiya R., Taylor A.N. Genetic differences in opiate receptor concentration and sensitivity to ethanol's effects. Pharmacol. Biochem. Behav. 33:1989;793-796
62. Nylander I., Hyytia P., Forsander O., Terenius L. Differences between alcohol-preferring (AA) and alcohol-avoiding (ANA) rats in the prodynorphin and proenkephalin systems. Alcohol. Clin. Exp. Res. 18:1994;1272-1279
63. Fadda F., Tronci S., Colombo G., Fratta W. Differences in the opioid system in selected brain regions of alcohol-preferring and alcohol-nonpreferring rats. Alcohol. Clin. Exp. Res. 23:1999;1296-1305
64. Turchan J., Przewlocka B., Toth G., Lason W., Borsodi A., Przewlocki R. The effect of repeated administration of morphine, cocaine and ethanol on mu and delta opioid receptor density in the nucleus accumbens and striatum of the rat. Neuroscience. 91:1999;971-977
65. Marinelli P.W., Kiianmaa K., Gianoulakis C. Opioid propeptide mRNA content and receptor density in the brains of AA and ANA rats. Life Sci. 66:2000;1915-1927
66. Gianoulakis C., de Waele J.-P., Kiianmaa K. Differences in the brain and pituitary β-endorphin system between the alcohol-preferring AA and alcohol-avoiding ANA rats. Alcohol. Clin. Exp. Res. 16:1992;453-459
67. Jamensky N.T., Gianoulakis C. Comparison of the proopiomelanocortin and proenkephalin opioid peptide systems in brain regions of the alcohol-preferring 57BL/6 and alcohol-avoiding DBA/2 mice. Alcohol. 18:1999;177-187
68. De Waele J.-P., Gianoulakis C. Enhanced activity of the brain β-endorphin system by free-choice ethanol drinking in C57BL/6 but not DBA/2 mice. Eur. J. Pharmacol. 258:1994;119-129
69. Krishnan-Sarin S., Wand G.S., Li X.W., Portoghese P.S., Froehlich J.C. Effect of mu opioid receptor blockade on alcohol intake in rats bred for high alcohol drinking. Pharmacol. Biochem. Behav. 59:1998;627-635
70. Crabbe J.C., Keith L.D., Kosobud A., Stack J. Ethanol dependence and the pituitary-adrenal axis in mice: I. Genotypic differences in hormone levels. Life Sci. 33:1983;1877-1887
71. Blum K., Briggs A.H. Opioid peptides and genotypic responses to ethanol. Biog. Amines. 5:1988;527-533
72. Ng G.Y.K., O'Dowd B.F., George S.R. Genotypic differences in mesolimbic enkephalin gene expression in DBA/2J and C57BL/6J inbred mice. Eur. J. Pharmacol. 311:1996;45-52
73. Li X.-W., Li T.-K., Froehlich J.C. Enhanced sensitivity of the nucleus accumbens proenkephalin system to alcohol in rats selectively bred for alcohol preference. Brain Res. 794:1998;35-47
74. De Waele J.-P., Kiianmaa K., Gianoulakis C. Distribution of the μ and § opioid sites in the brain of the alcohol-preferring AA and alcohol-avoiding ANA lines of rats. J. Pharmacol. Exp. Ther. 275:1995;518-527
75. Jamensky N.T., Gianoulakis C. Content of dynorphins and κ-opioid receptors in distinct brain regions of C57BL/6 and DBA/2 mice. Alcohol. Clin. Exp. Res. 21:1997;1455-1464
76. De Waele J.-P., Gianoulakis C. Characterization of the μ and § opioid receptors in the brain of the C57BL/6 and DBA/2 mice, selected for their differences in voluntary ethanol consumption. Alcohol. Clin. Exp. Res. 21:1997;754-762
77. 3H] naltrindole in alcohol-preferring AA and alcohol-avoiding ANA rats. Alcohol. 15:1998;227-232
78. McBride W.J., Chernet E., McKinzie D.L., Lumeng L., Li T.-K. Quantitative autoradiography of mu-opioid receptors in the CNS of alcohol-naïve alcohol-preferring P and non-preferring NP rats. Alcohol. 16:1998;317-323
79. Gong J.H., Li X.W., Lai Z.N., Froehlich J.C., Yu L. Quantitative comparison of mu opioid receptor mRNA in selected CNS regions of alcohol naïve rats selectively bred for high and low alcohol drinking. Neurosci. Lett. 227:1997;9-12
80. Froehlich J.C., Harts J., Lumeng L., Li T.-K. Naloxone attenuates voluntary ethanol intake in rats selectively bred for high ethanol preference. Pharmacol. Biochem. Behav. 35:1990;385-390
81. Hubbell C.L., Czirr S.A., Hunter G.A., Beaman C.M., Lecann N.C., Reid L.D. Consumption of ethanol solution is potentiated by morphine and attenuated by naloxone persistently across repeated daily administrations. Alcohol. 3:1986;39-54
82. Marfang-Jallat P., Miceli D., Le Magnen J. Decrease in ethanol consumption by naloxone in naïve and dependent rats. Pharmacol. Biochem. Behav. 18(Suppl. 1):1983;537-539
83. Samson H.H., Doyle T.F. Oral ethanol-self-administration in the rat: effect of naloxone. Pharmacol. Biochem. Behav. 22:1985;92-99
84. Weiss F., Mitchiner M., Bloom F.E., Koob G.F. Free-choice responding for ethanol versus water in alcohol preferring (P) and unselected Wistar rats is differentially is modified by naloxone, bromocriptine, and methylsergide. Psychopharmacology. 101:1990;178-186
85. Altshuler H.L., Phillips P.E., Feinhandler D.A. Iteration of ethanol self-administration by naltrexone. Life Sci. 26:1980;679-688
86. Kornet M., Goosen C., Van Ree J.M. Effect of naltrexone on alcohol consumption during chronic alcohol drinking and after a period of imposed abstinence in free-choice drinking rhesus monkeys. Psychopharmacology (Berl.). 104:1991;367-376
87. Myers R.D., Borg S., Mossberg R. Antagonism by naltrexone of voluntary alcohol selection in the chronically drinking macaque monkey. Alcohol. 3:1986;383-388
88. Volpicelli J.R., Davis M.A., Olgin J.E. Naltrexone blocks the post-shock increase of ethanol consumption. Life Sci. 38:1986;841-847
89. Hubbell C.L., Marglin S.H., Spitalnic S.J., Abelson M.L., Wild K.D., Reid L.D. Opioidergic, serotonergic, and dopaminergic manipulation and rats' intake of a sweetened alcoholic beverage. Alcohol. 8:1991;355-367
90. Sharpe A.L., Samson H.H. Effect of naloxone on appetitive and consummatory phases of ethanol self-administration. Alcohol. Clin. Exp. Res. 25:2001;1006-1011
91. Linseman M.A., Le A.D. Effects of opioids on the absorption of alcohol. Pharmacol. Biochem. Behav. 58:1997;79-84
92. Morgan C.J., Badawy A.A., Thomas D.R., Dando T.G., Kirby A. The [lactate]/[pyruvate] ratio and alcohol metabolism: experiments with naloxone in fasting normal male volunteers. Alcohol Alcohol. 24:1989;185-188
93. Sinclair JD. Method for treating alcohol-drinking response. USA Patent 4, 882, 335, 1989.
94. Sinclair J.D. Evidence about the use of naltrexone and for different ways of using it in the treatment of alcoholism. Alcohol Alcohol. 36:2001;2-10
95. Froehlich J.C., Zweifel M., Harts J., Lumeng L., Li T.-K. Importance of delta opioid receptors in maintaining high alcohol drinking. Psychopharmacology. 103:1991;467-472
96. Krishnan-Sarin S., Jing S.-L., Kurtz D.L., Zweifel M., Portoghese P.S., Li T.-K., et al. The delta opioid receptor antagonist naltridole attenuates both alcohol and saccharin intake in rats selectively bred for alcohol preference. Psychopharmacology. 120:1995;177-185
97. Krishnan-Sarin S., Jing S.L., Kurtz D.L., Zweifel M., Portoghese P.S., Li T.K., et al. The delta opioid receptor antagonist naltrindole attenuates both alcohol and saccharin intake in rats selectively bred for alcohol preference. Psychopharmacology (Berl.). 120:1995;177-185
98. Froehlich J.C., Badia-Elder N.E., Zink R.W., McCullough D.E., Portoghese P.S. Contribution of the opioid system to alcohol aversion and alcohol drinking behavior. J. Pharmacol. Exp. Ther. 287:1998;284-292
99. Hyytia P. Involvement of mu-opioid receptors in alcohol drinking by alcohol-preferring AA rats. Pharmacol. Biochem. Behav. 45:1993;697-701
100. Acquas E., Meloni M., Di Chiara G. Blockade of δ-opioid receptors in the nucleus accumbens prevents ethanol-induced stimulation of dopamine release. Eur. J. Pharmacol. 230:1993;239-241
101. Widdowson P.S., Holman R.B. Ethanol-induced increase in endogenous dopamine release may involve endogenous opiates. J. Neurochem. 59:1992;157-163
102. Mansour A., Fox C.A., Akil H., Watson S.J. Opioid-receptor mRNA expression in the rat CNS: anatomical and functional implications. Trends Neurosci. 18:1995;22-29
103. Heyser C.J., Roberts A.J., Schulties G., Koob G.F. Central administration of an opiate antagonist decreases oral ethanol self-administration in rats. Alcohol. Clin. Exp. Res. 23:1999;1468-1476
104. Koob G.F., Roberts A.J. Brain reward circuits in alcoholism. CNS Spectr. 4:1999;23-37
105. McBride W.J. Central nucleus of the amygdala and the effects of alcohol and alcohol-drinking behavior in rodents. Pharmacol. Biochem. Behav. 71:2002;509-515
106. Koob G.F. The role of the striatopallidal and extended amygdala systems in drug addiction. Ann. N. Y. Acad. Sci. 877:1999;445-459
107. Myers R.D., Robinson D.E. Mu and D2 receptor antisense oligonucleotides injected in nucleus accumbens suppress high alcohol intake in genetic drinking HEP rats. Alcohol. 18:1999;225-233
108. Roberts A.J., Gold L.H., Polis I., McDonald J.S., Filliol D., Kieffer B.L., et al. Increased ethanol self-administration in delta-opioid receptor knockout mice. Alcohol. Clin. Exp. Res. 25:2001;1249-1256
109. Goody R.J., Oakley S.M., Filliol D., Kieffer B.L., Kitchen I. Quantitative autoradiographic mapping of opioid receptors in the brain of delta-opioid receptor gene knockout mice. Brain Res. 945:2002;9-19
110. Hall F.S., Sora L., Li X.-F., Karmacharya N., Goodman N., Uhl G.R. Decreased responses to ethanol in μ opiate receptor knockout mice. [abstract 535.17] Society for neuroscience abstracts of the 29th annual meeting. vol. 25:1999;1327 Society for Neuroscience, Washington (DC)
111. Graham N.J., Low M.J., Cunningham C.L. Intravenous self-administration of ethanol in β-endorphin-deficient mice. Alcohol. Clin. Exp. Res. 22:1998;1093-1098
112. Grisel J.E., Mogil J.S., Grahame N.J., Rubinstein M., Bellknap J.K., Crabbe J.C., et al. Ethanol oral self-administration is increased in mutant mice with decreased beta-endorphin expression. Brain Res. 835:1999;6267
113. Genazzani A.R., Nappi G., Facchinetti F. Central deficiency in beta-endorphin in alcohol addicts. J. Clin. Endocrinol. Metab. 55:1982;583-586
114. Aguirre J.C., Del Arbol J.L., Raya J., Ruiz M.E., Rico J. Plasma β-endorphin levels in chronic alcoholics. Alcohol. 7:1990;409-412
115. Inder W.J., Livesey J.H., Donald R.A. Peripheral plasma levels of beta-endorphin in alcoholics and highly trained athletes and the relationship to a measure of central opioid tone. Horm. Metab. Res. 30:1998;523-525
116. Marchesi C., Chiodera P., Ampollini P., Volpi R., Coiro V. Beta-endorphin, adrenocorticotropic hormone and cortisol secretion in abstinent alcoholics. Psychiatry Res. 72:1997;187-194
117. Vescovi P.P., DiGennaro C., Coiro V. Hormonal (ACTH, cortisol, beta-endorphin, and Met-enkephalin) and cardiovascular responses to hyperthermic stress in chronic alcoholics. Alcohol. Clin. Exp. Res. 21:1997;1195-1998
118. Gianoulakis C., Beliveau D., Angelogianni P., Meaney M., Thavundayil J., Tawar V., et al. Different pituitary β-endorphin and adrenal cortisol response to ethanol in individuals with high and low risk for future development of alcoholism. Life Sci. 45:1989;1097-1109
119. Gianoulakis C., Krishnan B., Thavumdayil J. Enhanced sensitivity of pituitary β-endorphin to ethanol in subjects at high risk of alcoholism. Arch. Gen. Psychiatry. 53:1996;250-257
120. Froehlich J.C., Zink R.W., Li T.K., Christian J.C. Analysis of heritability of hormonal responses to alcohol in twins: beta-endorphin as a potential biomarker of genetic risk for alcoholism. Alcohol. Clin. Exp. Res. 24:2000;265-277
121. Gianoulakis C. Alcohol-seeking behavior. The roles of the hypothalamic-pituitary-adrenal axis and the endogenous opioid system. Alcohol Health Res. World. 22:1998;202-210
122. Dai X., Thavundayil J., Gianoulakis C. Differences in the responses of the pituitary β-endorphin and cardiovascular system to ethanol and stress as a function of family history. Alcohol. Clin. Exp. Res. 26:2002;1171-1180
123. Drolet G., Dumont E.C., Gosselin I., Kinkead R., Laforest S., Trottier J.-F. Role of endogenous opioid system in the regulation of the stress response. Prog. Neuropsychopharmacol. Biol. Psychiatry. 25:2001;729-741
124. Fahlke C., Hard E., Thomasson R., Engel J.A., Hansen S. Metyrapone-induced suppression of corticosterone synthesis reduces ethanol consumption in high-preferring rats. Pharmacol. Biochem. Behav. 48:1994;977-981
125. Marinelli M., Piazza P.V., Deroche V., Maccari S., Le Moal M., Simon H. Corticosterone circadian secretion differentially facilitates dopamine-mediated psychomotor effect of cocaine and morphine. J. Neurosci. 14:1994;2724-2731
126. Piazza P.V., Le Moal M. Glucocorticoids as a biological substrate of reward: physiological and pathophysiological implications. Brain Res. Rev. 25:1997;359-372
127. Reid M.S., Ho L.B., Tolliver B.K., Wolkowitz O.M., Berger S.P. Partial reversal of stress-induced behavioral sensitization to amphetamine following metyrapone treatment. Brain Res. 783:1998;133-142
128. Tsagarakis S., Rees L.H., Besser M., Grossman A. Opiate receptor subtype regulation of CRF-41 release from rat hypothalamus in vitro. Neuroendocrinology. 51:1990;599-605
129. Calogero A.E. Neurotransmitter regulation of the hypothalamic corticotropin-releasing hormone neuron. Ann. N. Y. Acad. Sci. 771:1995;31-40
130. Kreek M.J. Opioid receptors: some perspectives from early studies of their role in normal physiology, stress responsivity, and in specific addictive diseases. Neurochem. Res. 21:1996;1469-1488
131. Valentino R.J., Van Bockstaele E. Opposing regulation of the locus coeruleus by corticotropin-releasing factor and opioids: potential for reciprocal interactions between stress and opioid sensitivity. Psychopharmacology. 158:2001;331-342
132. Kreek M.J., Koob G.F. Drug dependence: stress and dysregulation of brain reward pathways. Drug Alcohol Depend. 51:1998;23-47
133. Yajima F., Suda T., Tomori N., Sumitomo T., Nakagami Y., Ushiyama T., et al. Effects of opioid peptides on immunoreactive corticotropin-releasing factor release from the rat hypothalamus in vitro. Life Sci. 39:1986;181-186
134. Chrousos G.P., Gold P.W. The concepts of stress and stress system disorders. Overview of physical and behavioral homeostasis. JAMA. 267:1992;1244-1262
135. Bujdoso E., Jaszberenyi M., Tomboly C., Toth G., Telegdy G. Behavioral and neuroendocrine actions of endomorphin-2. Peptides. 22:2001;1459-1463
136. Grossman A., Besser G.M. Opiates control ACTH through a noradrenergic mechanism. Clin. Endocrinol. 17:1982;287-290
137. Sim-Selley L.J., Xiao R., Childers S.R. Anatomical distribution of sodium-dependent [3H] naloxone bindings sites in rat brain. Synapse. 35:2000;256-264
138. Wand G.S., Dobs A.S. Alterations in the hypothalamic-pituitary-adrenal axis in actively drinking alcoholics. J. Clin. Endocrinol. Metab. 72:1991;1290-1295
139. Adinoff B., Anton R., Linnoila M., Guidotti A., Nemeroff C.B., Bissette G. Cerebrospinal fluid concentrations of corticotropin-releasing hormone (CRH) and diazepam-binding inhibitor (DBI) during alcohol withdrawal and abstinence. Neruopsychopharmacology. 15:1996;288-295
140. Costa A., Buno G., Marignoni E., Merlo P., Sances G., Nappi G. An assessment of HPA axis functioning in non-depressed, early abstinent alcoholics. Psychoneuroendocrinology. 21:1996;263-275
141. Hundt W., Zimmermann U., Pottig M., Spring K., Holsboer F. The combined dexamethasone-suppression/CRH-stimulation test in alcoholics during and after acute withdrawal. Alcohol. Clin. Exp. Res. 25:2001;687-691
142. Inder W.J., Joyce P.R., Ellis M.J., Evans M.J., Livesey J.H., Donald R.A. The effects of alcoholism on the hypothalamic-pituitary-adrenal axis: interaction with endogenous opioid peptides. Clin. Endocrinol. 43:1995;283-290
143. Lex B.W., Ellingboe J.E., Teoh S.K., Mendelson J.H., Rhoades E. Prolactin and cortisol levels following acute alcohol challenges in women with and without a family history of alcoholism. Alcohol. 8:1991;383-387
144. Schuckit M.A. Subjective responses to alcohol in sons of alcoholics and control subjects. Arch. Gen. Psychiatry. 41:1984;879-884
145. Waltman C., McCaul M.E., Wand G.S. Adrenocorticotropin responses following administration of ethanol and ovine corticotropin-releasing hormone in the sons of alcoholics and control subjects. Alcohol. Clin. Exp. Res. 18:1994;330-826
146. Cintra A., Zoli M., Rosen L., Agnati L.F., Okret S., Wikstrom A.C., et al. Mapping and computer assisted morphometry and microdensitometry of glucocorticoid receptor immunoreactive neurons and glial cells in the rat central nervous system. Neuroscience. 62:1994;843-897
147. Harfstrand A., Fuxe K., Cintra A., Agnati L.F., Zini I., Wikstrom A.C., et al. Glucocorticoid receptor immunoreactivity in monoaminergic neurons of rat brain. Proc. Natl. Acad. Sci. U. S. A. 83:1986;9779-9783
148. Gianoulakis C. Alcohol-seeking behavior. The roles of the hypothalamic-pituitary-adrenal axis and the endogenous opioid system. Alcohol Health Res. World. 22:1998;202-210
149. Wand G.S., Mangold D., El Deiry S., McCaul M.E., Hoover D. Family history of alcoholism and hypothalamic opioidergic activity. Arch. Gen. Psychiatry. 55:1998;1114-1119
150. Wand G.S., Mangold D., Ali M. Adrenocorticotropin responses to naloxone in sons of alcohol-dependent men. J. Clin. Endocrinol. Metab. 84:1999;64-68
151. Wand G.S., Mangold D., Ali M., Giggey P. Adrenocortical responses and family history of alcoholism. Alcohol. Clin. Exp. Res. 23:1999;1185-1190
152. Mangold D., McCaul M.E., Ali M., Wand G.S. Plasma adrenocorticotropin responses to opioid blockade with naloxone: generating a dose-response curve in a single session. Biol. Psychiatry. 48:2000;310-314
153. Kemper A., Koalick F., Thiele H., Retzow A., Rathsack R., Nickel B. Cortisol and β-endorphin response in alcoholics and alcohol abusers following a high naloxone dosage. Drug Alcohol Depend. 25:1990;319-326
154. Wand G.S., McCaul M.E., Gotjen D., Reynolds J., Lee S. Confirmation that offspring from families with alcohol-dependent individuals have greater hypothalamic-pituitary-adrenal axis activation induced by naloxone compared with offspring without a family history of alcohol dependence. Alcohol. Clin. Exp. Res. 25:2001;1134-1139
155. Hernandez-Avila C.A., Oncken C., Van Kirk J., Wand G., Kranzler H.R. Adrenocorticotropin and cortisol responses to a naloxone challenge and risk of alcoholism. Biol. Psychiatry. 51:2002;652-658
156. Insel T.R., Pickar D. Naloxone administration in obsessive-compulsive disorder: report of two cases. Am. J. Psychiatry. 140:1983;1219-1220
157. Keuler D.J., Altemus M., Michelson D., Greenberg B., Murphy D.L. Behavioral effects of naloxone infusion in obsessive-compulsive disorder. Biol. Psychiatry. 40:1996;154-156
158. Sandyk R. Naloxone abolishes obsessive-compulsive behavior in Tourette's syndrome. Int. J. Neurosci. 35:1987;93-94
159. Rapoport J.L. Obsessive compulsive disorder and basal ganglia dysfunction. Psychol. Med. 20:1990;465-469
160. Rapoport J.L., Ryland D.H., Kriete M. Drug treatment of canine acral lick: an animal model of obsessive-compulsive disorder. Arch. Gen. Psychiatry. 49:1992;517-521
161. Stein D.J., Dodman N.H., Borchelt P., Hollander E. Behavioral disorders in veterinary practice: relevance to psychiatry. Compr. Psychiatry. 35:1994;275-285
162. O'Malley S.S., Jaffe A.J., Chang G., Schottenfeld R.S., Meyer R.E., Rounsaville B. Naltrexone and coping skills therapy for alcohol dependence. Arch. Gen. Psychiatry. 49:1992;881-887
163. Volpicelli J.R., Alterman A.I., Hayashida M., O'Brien C.P. Naltrexone in the treatment of alcohol dependence. Arch. Gen. Psychiatry. 49:1992;876-880
164. Davidson A.F., Emm T.A., Pieniaszek H.J. Determination of naltrexone and its major metabolite, 6-beta-naltrexol, in human plasma using liquid chromatography with electrochemical detection. J. Pharm. Biomed. Anal. 14:1996;1717-1725
165. Gonzalez J.P., Brogden R.N. Naltrexone: a review of its pharmacodynamic and pharmacokinetic properties and therapeutic efficacy in the management of opioid dependence. Drugs. 35:1988;192-213
166. Ferrari A., Bertolotti M., Dell'Utri A., Avico W., Sternieri E. Serum time course of naltrexone and 6-beta-naltrexol levels during long term treatment in drug addicts. Drug Alcohol Depend. 52:1998;211-220
167. Meyer M., Straughn A., Lo M.-W., Schary W.L., Whitney C.C. Bioequivalence, dose-proportionality and pharmacokinetics of naltrexone after oral administration in a new approach to the management of opioid dependence. J. Clin. Psychiatry. 45:1984;15-19
168. Anton R.F., Moak D.H., Waid R., Latham P.K., Malcolm R.J., Dias J.K. Naltrexone and cognitive behavioral therapy for the treatment of outpatient alcoholics: results of a placebo-controlled trial. Am. J. Psychiatry. 156:1999;1758-1764
169. Morris P.L.P., Hopwood M., Whelan G., Gardiner J., Drummond E. Naltrexone for alcohol dependence: a randomized controlled trial. Addiction. 96:2001;1565-1573
170. O'Malley S.S., Jaffe A.J., Chang G., Rode S., Schottenfeld R., Meyer R.E., et al. Six-month follow-up of naltrexone and psychotherapy for alcohol dependence. Arch. Gen. Psychiatry. 53:1996;217-224
171. Chick J., Anton R., Checinski K., Croop R., Drummond C., Farmer R., et al. A multicentre, randomized, double-blind, placebo-controlled trial of naltrexone in the treatment of alcohol dependence or abuse. Alcohol Alcohol. 35:2000;587-593
172. Guardia J., Caso C., Arias F., Guai A., Sanahuja J., Ramirez M., et al. A double-blind, placebo-controlled study of naltrexone in the treatment of alcohol-dependence disorder: results form a multicenter clinical trial. Alcohol. Clin. Exp. Res. 26:2002;1381-1387
173. Krystal J.H., Cramer J.A., Krol W.F., Kirk G.F., Rosenheck R.A.
174. Heinala P., Alho H., Kiianmaa K., Lonnqvist J., Kuoppasalmi K., Sinclair J.D. Targeted use of naltrexone without prior detoxification in the treatment of alcohol dependence: a factorial double-blind, placebo-controlled trial. J. Clin. Psychopharmacol. 21:2001;287-292
175. Johnson B.A., Ait-Daoud N. Neuropharmacological treatments for alcoholism: scientific basis and clinical findings. Psychopharmacology. 149:2000;327-344
176. Volpicelli J.R., Rhines K.C., Rhines J.S., Volpicelli L.A., Alterman A.I., O'Brian C.P. Naltrexone and alcohol dependence: role of subject compliance. Arch. Gen. Psychiatry. 54:1997;737-742
177. McCaul M.E., Wand G.S., Sullivan J., Mumford G., Quigley J. Beta-naltrexol level predicts alcohol relapse (abstract). Alcohol. Clin. Exp. Res. 21:1997;32A
178. Kranzler H.R., Modesto-Lowe V., Van Kirk J. Naltrexone vs. nefazodone for treatment of alcohol dependence. A placebo controlled trial. Neuropsychopharmacology. 22:2000;493-503
179. McEvoy G.K. AHFS drug information. 1997;1619-1626 American Society of Health-System Pharmacists, Bethesda (MD)
180. Kranzler H.R., Modesto-Lowe V., Nuwayser E.S. A sustained-release naltrexone preparation for treatment of alcohol dependence. Alcohol. Clin. Exp. Res. 22:1998;1074-1079
181. Anton R.F., Moak D., Latham P.K., Waid R., Malcolm R.J., Dias J.K., et al. Posttreatment results of combining naltrexone with cognitive-behavior therapy for the treatment of alcoholism. J. Clin. Psychopharmacol. 21:2001;72-77
182. Rubio G., Jimenez-Arriero M.A., Ponce G., Palomo T. Naltrexone versus acamprosate: one year follow-up of alcohol dependence treatment. Alcohol Alcohol. 36:2001;419-425
183. Diaz A., Pazos A., Florez J., Ayesta F.J., Santana V., Hurle M.A. Regulation of mu-opioid receptors, G-protein-coupled receptor kinases and beta-arrestin 2 in the rat brain after chronic opioid receptor antagonism. Neuroscience. 112:2002;345-353
184. Narita M., Mizoguchi H., Nagase H., Suzuki T., Tseng L.F. Up-regulation of spinal mu-opioid receptor function to activate G-protein by chronic naloxone treatment. Brain Res. 913:2001;170-173
185. Schluger J.H., Ho A., Borg L., Porter M., Maniar S., Gunduz M., et al. Nalmefene causes greater hypothalamic-pituitary-adrenal axis activation than naloxone in normal volunteers: implications for the treatment of alcoholism. Alcohol. Clin. Exp. Res. 22:1998;1430-1436
186. Wang D.S., Sternbach G., Varon J. Nalmefene: a long-acting opioid antagonist. Clinical applications in emergency medicine. J. Emerg. Med. 16:1998;471-475
187. Mason B.J., Salvato F.R., Williams L.D., Ritvo E.C., Cutler R.B. A double-blind, placebo-controlled study of oral nalmefene for alcohol dependence. Arch. Gen. Psychiatry. 56:1999;719-724
188. Volpicelli J.R., Watson N.T., King A.C., Sherman C.E., O'Brien C.P. Effect of naltrexone on alcohol "high" in alcoholics. Am. J. Psychiatry. 152:1995;613-615
189. Davidson D., Palfai T., Bird C., Swift R. Effects of naltrexone on alcohol self-administration in heavy drinkers. Alcohol. Clin. Exp. Res. 23:1999;195-203
190. de Wit H., Svenson J., York A. Non-specific effect of naltrexone on ethanol consumption in social drinkers. Psychopharmacology. 146:1999;33-41
191. McCaul M.E., Wand G.S., Eissenber T., Rohde C.A., Cheskin L.J. Naltrexone alters subjective and psychomotor responses to alcohol in heavy drinking subjects. Neuropsychopharmacology. 22:2000;480-492
192. Florez J., Hurle M.A. Opioids in respiration and vomiting. Herz A. Opioids II handbook of experimental pharmacology. vol. 104:1993;263-292 Springer-Verlag, New York
193. Faden A.I. Role of endogenous opioids in central and cardiovascular regulation and dysregulation. Herz A. Opioids II handbook of experimental pharmacology. vol. 104:1993;191-204 Springer-Verlag, New York
194. Kosterlitz H.W., Waterfield A.A. In vitro models in the study of structure-activity relationships of narcotic analgesics. Annu. Rev. Pharmacol. 15:1975;29-47
195. Akil H., Watson S., Young E., Lewis M.E., Khachaturian H., Walker J.W. Endogenous opioids: biology and function. Annu. Rev. Neurosci. 7:1984;223-255
196. Cooper S.J., Kirkham T.C. Opioid mechanisms in the control of food consumption and taste preferences. Herz A. Opioids II handbook of experimental pharmacology. vol. 104:1993;239-262 Springer-Verlag, New York
197. Hayward M.D., Pintar J.E., Low M.J. Selective reward deficit in mice lacking beta-endorphin and enkephalin. J. Neurosci. 22:2002;8251-8258
198. Rudski J.M., Billington C.J., Levine A.S. A sucrose-based maintenance diet increases sensitivity to appetite suppressant effects of naloxone. Pharmacol. Biochem. Behav. 58:1997;679-682
199. Schwarz-Stevens K.S., Files F.J., Samson H.H. Effects of morphine and naloxone on ethanol- and sucrose-reinforced responding in nondeprived rats. Alcohol. Clin. Exp. Res. 16:1992;822-832
200. Williams K.L., Winger G., Pakarinen E.D., Woods J.H. Naltrexone reduces ethanol- and sucrose-reinforced responding in rhesus monkeys. Psychopharmacology (Berl.). 139:1998;53-61
201. Doty P., de Wit H. Effects of naltrexone pretreatment on the subjective and performance effects of ethanol in social drinkers. Behav. Pharmacol. 6:1995;386-394
202. Doty P., Kirk J.M., Cramblett M.J., de Wit H. Behavioral responses to ethanol in light and moderate social drinkers following naltrexone pretreatment. Drug Alcohol. Depend. 47:1997;109-116
203. Swift R.M., Whelihan W., Kuznetsov O., Buongiorno G., Hsuing H. Naltrexone-induced alterations in human ethanol intoxication. Am. J. Psychiatry. 151:1994;1463-1467
204. King A.C., Volpicelli J.R., Fraxer A., O'Brian C.P. Effect of naltrexone on subjective alcohol response in subjects at high and low risk for future alcohol dependence. Psychopharmacology. 129:1997;15-22
205. King A.C., Schluger J., Gunduz M., Borg L., Perret G., Ho A., et al. Hypothalamic-pituitary-adrenocortical (HPA) axis response and biotransformation of oral naltrexone: preliminary examination of relationship to family history of alcoholism. Neuropsychopharmacology. 26:2002;778-788
206. O'Malley S.S., Krishnan-Sarin S., Farren C., Sinha R., Kreek M.J. Naltrexone decreases craving and alcohol self-administration in alcohol-dependent subjects and activates the hypothalamo-pituitary- adrenocortical axis. Pscyhopharmacology. 160:2002;19-29
207. O'Malley S.S., Krishnan-Sarin S., Farren C.K., O'Connor P.G. Naltrexone induced nausea in patients treated for alcohol dependence: clinical predictors and evidence for opioid mediated effects. J. Clin. Psychopharmacol. 20:2001;69-76
208. McCaul M.E., Wand G.S., Rohde C., Lee S.M. Serum 6-beta-naltrexol levels are related to alcohol responses in heavy drinkers. Alcohol. Clin. Exp. Res. 24:2000;1385-1391
209. McCaul M.E., Wand G.S., Stauffer R., Lee S.M., Rohde C.A. Naltrexone dampens ethanol-induced cardiovascular and hypothalamic-pituitary-adrenal axis activation. Neuropsychopharmacology. 25:2001;537-547
210. Cloninger R., Bohman M., Sigvardsson S. Inheritance of alcohol abuse: cross-fostering analysis of adopted men. Arch. Gen. Psychiatry. 38:1981;861-868
211. Goldman D., Linnoila M. Genetic approaches to alcoholism. Prog. Neuropsychopharmacol. Biol. Psychiatry. 10:1986;237-242
212. Pickens R.W., Dace S.S., McGue M., Lykken D.T., Heston L.L., Clayton P.J. Heterogeneity in the inheritance of alcoholism: a study of male and female twins. Arch. Gen. Psychiatry. 48:1991;19-28
213. LaForge K.S., Yuferov V., Kreek M.J. Opioid receptor and peptide gene polymorphisms: potential implications for addictions. Eur. J. Pharmacol. 410:2000;249-268
214. Bergen A.W., Kokoszka J., Peterson R., Long J.C., Virkkunen M., Linnoila M., et al. Mu-opioid receptor gene variants: lack of association with alcohol dependence. Mol. Psychiatry. 2:1997;490-494
215. Wendel B., Hoehe R.R. The human mu-opioid receptor gene: 5 regulatory and intronic sequences. J. Mol. Med. 76:1998;525-532
216. Bond C., LaForge K.S., Tian M., Melia D., Zhang S., Borg L., et al. Single-nucleotide polymorphism in the human mu-opioid receptor gene alters beta-endorphin binding and activity: possible implications for opiate addiction. Proc. Natl. Acad. Sci. U. S. A. 95:1998;9608-9613
217. J Gelernter, H Kranzler, J Cubells. Genetics of two μ opioid receptor gene (OPRM1) exon 1 polymorphism: population studies, and allele frequencies in alcohol- and drug-dependent subjects. Mol Psychiatry 4:476-483.
218. Rommelspacher H., Smolka M., Schmidt L.G., Samochowiec J., Hoehe M.R. Genetic analysis of the μ-opioid receptor in alcohol-dependent individuals. Alcohol. 24:2001;129-135
219. Sander T., Gscheidel N., Wendel B., Samochowiec J., Smolka M., Rommelspcher H., et al. Human μ-opioid receptor variation and alcohol dependence. Alcohol. Clin. Exp. Res. 22:1998;2108-2110
220. Town T., Abdullah L., Crawford F., Schinka J., Ordorica P.I., Francis E., et al. Association of a functional μ-opioid receptor allele (+118A) with alcohol dependency. Am. J. Med. Genet. 88:1999;458-461
221. Town T., Schinka J., Tan J., Mullan M. The opioid receptor system and alcoholism: a genetic perspective. Eur. J. Pharmacol. 410:2000;243-248
222. Comings D.E., Blum K. Reward deficiency syndrome: genetic aspects of behavioral disorders. Prog. Brain. Res. 126:2000;325-341
223. Wand G.S., McCaul M., Yang X., Reynolds J., Gotjen D., Lee S., et al. The mu-opioid receptor gene polymorphism (A118G) alters HPA axis activation induced by opioid receptor blockade. Neuropsychopharmacology. 26:2002;106-114
224. Oslin D.W., Berrettini W., Kranzler H.R., Pettinati H., Gelernter J., Volpicel J.R., et al. A functional polymorphism of the mu-opioid receptor gene is associated with naltrexone response in alcohol-dependent patients. Neuropsychopharmacology. 28:2003;1546-1552
225. Cloninger C.R., Pryzbeck T.R., Svrakic D.M. The tridimensional personality questionnaire: U.S. normative data. Psychol. Rep. 69:1991;1047-1057
226. Lotsch J., Skarke C., Grosch S., Darimont J., Schmidt H., Geisslinger G. The polymorphism A118G of the human mu-opioid receptor gene decreases the pupil constrictory effect of morphine-6-glucuronide but not that of morphine. Pharmacogenetics. 12:2002;3-9
227. Volkow N.D., Wang G.J., Fowler J.S., Logan J., Hitzemann R., Ding Y.S., et al. Decreases in dopamine receptors but not in dopamine transporters in alcoholics. Alcohol Clin. Exp. Res. 20:1996;1594-1598
228. Volkow N.D., Fowler J.S., Wolf A.P., Schlyer D., Shiue C.Y., Alpert R., et al. Effects of chronic cocaine abuse on postsynaptic dopamine receptors. Am. J. Psychiatry. 147:1990;719-724
229. Volkow N.D., Wang G.J., Fowler J.S., Thanos P., Logan J., Gatley S.J., et al. Brain DA D2 receptors predict reinforcing effects of stimulants in humans: replication study. Synapse. 46:2002;79-82
230. Schuckit M.A., Parker D.C., Rossman L.R. Ethanol-related prolactin responses and risk for alcoholism. Biol. Psychiatry. 18:1983;1153-1159
231. Noble E. The D2 dopamine receptor gene: a review of association studies in alcoholism and phenotypes. Alcohol. 16:1998;33-45
232. Zeise M., Kasparow S., Capogna M., Zieglgansberger W. Acamprosate (calcium homotaurinate) decreases postsynaptic potentials in the rat neocortex: possible involvement of excitatory amino acid receptors. Eur. J. Pharmacol. 231:1993;47-52
233. Froehlich J.C. Opioid peptides. Alcohol Health Res. World. 21:1997;132-136